Canada
· Delayed Price · Currency is CAD Aion Therapeutic Statistics
Total Valuation
Aion Therapeutic has a market cap or net worth of CAD 7.46 million. The enterprise value is 9.14 million.
| Market Cap | 7.46M |
| Enterprise Value | 9.14M |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aion Therapeutic has 497.15 million shares outstanding. The number of shares has increased by 38.05% in one year.
| Shares Outstanding | 497.15M |
| Shares Change (YoY) | +38.05% |
| Shares Change (QoQ) | +65.98% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | n/a |
| Float | 450.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.53 |
| PB Ratio | 5.98 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.34 |
| EV / Sales | 41.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18, with a Debt / Equity ratio of 197.01.
| Current Ratio | 0.18 |
| Quick Ratio | 0.10 |
| Debt / Equity | 197.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -15.90% |
| Return on Capital (ROIC) | -48.33% |
| Revenue Per Employee | 44,409 |
| Profits Per Employee | -219,313 |
| Employee Count | 5 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.55 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 53.94 |
| Average Volume (20 Days) | 19,391 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aion Therapeutic had revenue of CAD 222,043 and -1.10 million in losses. Loss per share was -0.01.
| Revenue | 222,043 |
| Gross Profit | 163,721 |
| Operating Income | -828,970 |
| Pretax Income | -1.10M |
| Net Income | -1.10M |
| EBITDA | -825,501 |
| EBIT | -828,970 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 349,283 in cash and 2.03 million in debt, giving a net cash position of -1.69 million or -0.00 per share.
| Cash & Cash Equivalents | 349,283 |
| Total Debt | 2.03M |
| Net Cash | -1.69M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 1.03M |
| Book Value Per Share | 0.00 |
| Working Capital | -3.97M |
Cash Flow
| Operating Cash Flow | 115,402 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 73.73% |
| Operating Margin | -373.34% |
| Pretax Margin | -493.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aion Therapeutic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.05% |
| Shareholder Yield | -38.05% |
| Earnings Yield | -36.51% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aion Therapeutic has an Altman Z-Score of -5.88. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.88 |
| Piotroski F-Score | n/a |